Your browser doesn't support javascript.
loading
Venous thromboembolism and anticoagulation in spinal cord lesion rehabilitation inpatients: A 10-year retrospective study.
Bluvshtein, Vadim; Catz, Amiram; Mahamid, Ala; Elkayam, Keren; Michaeli, Dianne; Front, Lilach; Kfir, Adi; Gelernter, Ilana; Aidinoff, Elena.
Afiliación
  • Bluvshtein V; Department of Spinal Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.
  • Catz A; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Mahamid A; Department of Spinal Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.
  • Elkayam K; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Michaeli D; Department of Spinal Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.
  • Front L; Department of Spinal Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.
  • Kfir A; Department of Spinal Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.
  • Gelernter I; Department of Spinal Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.
  • Aidinoff E; Department of Spinal Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.
NeuroRehabilitation ; 53(1): 143-153, 2023.
Article en En | MEDLINE | ID: mdl-37424485
ABSTRACT

BACKGROUND:

Venous thromboembolism (VTE) is a concern following the onset of spinal cord lesions (SCL).

OBJECTIVES:

To assess the current efficacy and risks of anticoagulation after SCL and consider changes in thromboprophylaxis.

METHODS:

This retrospective cohort study included individuals admitted to inpatient rehabilitation within 3 months of SCL onset. Main outcome measures were the incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), bleeding, thrombocytopenia, or death, which occurred within 1 year of the SCL onset.

RESULTS:

VTE occurred in 37 of the 685 patients included in the study (5.4%, 95% CI 3.7-7.1%, 2.8% PE), and in 16 of 526 patients who received prophylactic anticoagulation at rehabilitation (3%, 95% CI 1.6-4.5%, 1.1% PE, with at least 1 fatality). Of these 526, 1.3% developed clinically significant bleeding and 0.8% thrombocytopenia. Prophylactic anticoagulation, most commonly 40 mg/day, continued until a median period of 6.4 weeks after SCL onset (25% -75% percentiles 5.8-9.7), but in 29.7%, VTE occurred more than 3 months after SCL onset.

CONCLUSION:

The VTE prophylaxis used for the present cohort contributed to a considerable but limited reduction of VTE incidence. The authors recommend conducting a prospective study to assess the efficacy and safety of an updated preventive anticoagulation regimen.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Embolia Pulmonar / Trombocitopenia / Tromboembolia Venosa Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: NeuroRehabilitation Asunto de la revista: NEUROLOGIA / REABILITACAO Año: 2023 Tipo del documento: Article País de afiliación: Israel

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Embolia Pulmonar / Trombocitopenia / Tromboembolia Venosa Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: NeuroRehabilitation Asunto de la revista: NEUROLOGIA / REABILITACAO Año: 2023 Tipo del documento: Article País de afiliación: Israel